Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

Valued at $13 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...